Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485914 | 0.94 | ALDH1A1 (0.36) | HDAC1HDAC4HDAC6HDAC2ALDH1A1 | |
| SCHEMBL30367749 | 0.94 | ALDH1A1 (0.36) | HDAC1HDAC4HDAC6HDAC2ALDH1A1 | |
| SCHEMBL5051961 | 0.91 | HDAC1 (0.33) | HDAC1HDAC4HDAC6HDAC2ALDH1A1 | |
| SCHEMBL29361373 | 0.89 | HPGD (0.37) | HDAC1HDAC4HDAC6HDAC2ALDH1A1 | |
| SCHEMBL44111 | 0.89 | HPGD (0.37) | HDAC1HDAC4HDAC6HDAC2ALDH1A1 | |
| SCHEMBL2033142 | 0.86 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL12056754 | 0.86 | HPGD (0.32) | HDAC1HDAC4HDAC6HDAC2 | |
| SCHEMBL19713428 | 0.86 | HPGD (0.35) | HDAC1HDAC4HDAC6HDAC2 | |
| SCHEMBL12056750 | 0.86 | HPGD (0.36) | HDAC1HDAC4HDAC6HDAC2 | |
| SCHEMBL2169209 | 0.84 | LMNA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172875-B2 | Therapeutic combinations comprising anti-FOLR1 immunoconjugates | IMMUNOGEN, INC. (US) | 2019-01-08 | — | — | US | claimed |
| CN-113039191-B | Nucleotide analogues | 奇异基因组学系统公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11691982-B2 | Thailanstatin analogs | PH PHARMA CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| US-20200407369-A1 | THAILANSTATIN ANALOGS | PH PHARMA CO., LTD. (KR) | 2020-12-31 | — | — | US | disclosed |
| US-10815246-B2 | Thailanstatin analogs | PH PHARMA CO., LTD. (KR) | 2020-10-27 | — | — | US | disclosed |
| EP-3684773-A1 | THAILANSTATIN ANALOGS | pH Pharma Co., Ltd. (KR) | 2020-07-29 | — | — | EP | disclosed |
| US-20200216463-A1 | THAILANSTATIN ANALOGS | PH PHARMA CO., LTD. (KR) | 2020-07-09 | — | — | US | disclosed |
| US-20190233430-A1 | THAILANSTATIN ANALOGS | PH PHARMA CO., LTD. (KR) | 2019-08-01 | — | — | US | disclosed |
| US-10301319-B2 | Thailanstatin analogs | PH PHARMA CO., LTD. (KR) | 2019-05-28 | — | — | US | disclosed |
| WO-2019060398-A1 | THAILANSTATIN ANALOGS | PH PHARMA CO., LTD. (KR) | 2019-03-28 | — | — | WO | disclosed |
| US-20170035905-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2017-02-09 | — | — | US | disclosed |
| US-20170035905-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2017-02-09 | — | — | US | disclosed |
| WO-2016188932-A2 | COMBINATION COMPOSITIONS AND THEIR USE IN METHODS FOR TREATING OBESITY AND OBESITY-RELATED DISORDERS | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-12-01 | — | — | WO | disclosed |
| US-9498543-B2 | Antibody drug conjugates | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | disclosed |
| US-9498543-B2 | Antibody drug conjugates | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | disclosed |
| US-20160030594-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-20150320880-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| WO-2014150937-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| US-20140271688-A1 | ANTIBODY DRUG CONJUGATES | IRM LLC (BM) | 2014-09-18 | — | — | US | disclosed |
| US-20140271688-A1 | ANTIBODY DRUG CONJUGATES | IRM LLC (BM) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233430-A1 | THAILANSTATIN ANALOGS | CD47, SUGT1, TPT1 | HDAC1 3176/4885HDAC4 2266/4885HDAC6 118/4885 |
| US-20160030594-A1 | ANTIBODY DRUG CONJUGATES | EPCAM, CD44, ABL1 | HDAC1 1738/4885HDAC4 755/4885HDAC6 26/4885 |
| US-10815246-B2 | Thailanstatin analogs | CD47, SUGT1, TPT1 | HDAC1 3176/4885HDAC4 2266/4885HDAC6 118/4885 |
| US-10301319-B2 | Thailanstatin analogs | CD47, SUGT1, TPT1 | HDAC1 3176/4885HDAC4 2266/4885HDAC6 118/4885 |
| US-20200216463-A1 | THAILANSTATIN ANALOGS | CD47, SUGT1, TPT1 | HDAC1 3176/4885HDAC4 2266/4885HDAC6 118/4885 |
| US-20200407369-A1 | THAILANSTATIN ANALOGS | CD47, SUGT1, TPT1 | HDAC1 3176/4885HDAC4 2266/4885HDAC6 118/4885 |
| US-20140271688-A1 | ANTIBODY DRUG CONJUGATES | EPCAM, CD44, ABL1 | HDAC1 1738/4885HDAC4 755/4885HDAC6 26/4885 |
| US-11691982-B2 | Thailanstatin analogs | CD47, SUGT1, TPT1 | HDAC1 3176/4885HDAC4 2266/4885HDAC6 118/4885 |
| US-20150320880-A1 | ANTIBODY DRUG CONJUGATES | EPCAM, CD44, ABL1 | HDAC1 1738/4885HDAC4 755/4885HDAC6 26/4885 |
| US-10172875-B2 | Therapeutic combinations comprising anti-FOLR1 immunoconjugates | FOLR1, FOLR2, DHFR | HDAC1 4208/4885HDAC4 4196/4885HDAC6 2849/4885 |
| US-20170035905-A1 | ANTIBODY DRUG CONJUGATES | EPCAM, CD44, ABL1 | HDAC1 1738/4885HDAC4 755/4885HDAC6 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.